Aegis Therapeutics is a drug-delivery and drug-formulation technologies company commercializing its patented drug delivery and protein stabilization technologies through product specific licenses to leading pharmaceutical and biopharmaceutical companies.

Aegis News

Aegis Awarded Russian Patent for Non-Invasive Delivery of Triptan Anti-Migraine Drugs

SAN DIEGO, CA  Sept. 1, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded its first Russian patent providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Russian Patent No. 2554814, titled: “Compositions for drug administration”, covers fast acting drug formulations utilizing Aegis’ […]

Aegis Therapeutics Awarded Third Patent for Metered Nasal Spray Parathyroid Hormone (PTH) Peptide Drug Formulations

SAN DIEGO, CA  Aug 27, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded US Patent No. 9,114,069 titled “Antibacterial Compositions for Drug Administration” providing non-toxic formulations of parathyroid hormone and related analogs, including teriparatide (PTH 1-34), suitable for injectable or metered nasal spray administration having intrinsic antimicrobial activity.  The patent formulations […]

Aegis Awarded Chinese and Japanese Patents for Non- Invasive Delivery of Triptan Anti-Migraine Drugs

SAN DIEGO, CA  Aug 11, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded foreign patents providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Chinese Patent No. ZL200980157305.0 and Japanese Patent No. 5752048, both titled: “Compositions for drug administration”, cover fast acting […]

Dauntless Pharmaceuticals and Aegis Therapeutics Announce Licensing Agreement

SAN DIEGO, July 21, 2015 /PRNewswire/ — Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis) today announced a licensing agreement providing Dauntless’ access to Aegis’ Intravail® drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Financial terms were not disclosed. […]

Aegis Awarded U.S. Patent No. 8,927,497 for Non- Invasive Delivery of Anti-Seizure Drugs

SAN DIEGO, CA Feb 18, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,927,497 providing broad coverage for non-invasive delivery of anti-seizure drugs via a simple metered nasal spray. The rapidly acting formulations utilize Aegis’ patented Intravail® transmucosal absorption enhancer technology. Aegis now has twenty-one issued patents related […]

Aegis Awarded 2nd Patent for Monoclonal Antibody Formulations that Avoid Oxidative Damage Due to Polysorbate Surfactants

SAN DIEGO, CA October 7, 2014/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,846,044, dramatically broadening its patent franchise to cover all useful alkylsaccharides for stabilizing any or all monoclonal antibody biotherapeutics. The Aegis ProTek® excipients provide reduced immunogenicity while avoiding the oxidative damage caused by contaminating peroxides and […]

First Non-Injectable GLP-1 Analog for Type-2 Diabetes

Aegis Offers Exclusive License for Patented Exenatide Metered Nasal Spray    San Diego, CA – August 5, 2014 – Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray  diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in […]

Aegis Awarded US Patent for Stable “Shirt-Pocket” Insulin Suitable for Metered Nasal Spray or Injection

SAN DIEGO, CA July 8, 2014/MarketWired– Aegis Therapeutics LLC announced today that it has been awarded its U.S. Patent No. 8,772,231 providing dramatically stabilized insulin formulations suitable for metered nasal spray delivery or injection based upon Aegis’ patented Intravail® transmucosal absorption enhancer and ProTek® protein stabilization technologies. While current insulin formulations denature in less than […]

First Non-Injectable Octreotide Available for License

Aegis Offers Exclusive License for Patented Octreotide Metered Nasal Spray San Diego, CA – July 2, 2014 – Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive octreotide metered nasal spray. Octreotide is a cyclic octapeptide indicated to reduce blood levels of growth hormone and IGF-I […]